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Abstract 
Backgound/Aims: Metabolic Syndrome is an emerging disease in developed countries and presents itself 
as a potential threat worldwide. The role of Diabetes, Dyslipidemia and Hepatic steatosis as pivotal 
participants in Metabolic Syndrome pathogenesis is well known. However, their common persistent 
chronic inflammation and its potential cause still elude. This systematic review aims to present evidence 
of the mechanisms that link the intestinal microbioma, innate immunity and Metabolic Syndrome.  
Methods: A comprehensive research was made using pubmed database and 35 articles were selected. 
Results: We found that metabolic syndrome is associated to increased levels of innate immunity 
receptors, namely, toll-like receptors, both at intestine and systemically and its polymorphisms may 
change the risk of metabolic syndrome development. Microbioma dysbiosis is also present in metabolic 
syndrome, with lower prevalence of Bacteroidetes and increased prevalence of Firmicutes populations. 
The data suggests that the link between Intestinal microbiota and Toll-like receptors can negatively 
endanger the metabolic homeostasis.  
Conclusion: Current evidence suggests that innate immunity and intestinal microbiota may be the hidden 
link in the Metabolic Syndrome development mechanisms. In the near future, this can be the key in the 
development of new prophylactic and therapeutic strategies to treat Metabolic Syndrome patients. 
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Introduction 
 
The Metabolic Syndrome presents itself as one as the principal chronic diseases 
of the developed countries and an important determinant of cardiovascular and 
metabolic mortality risk1. It is defined as a persistent pro-inflammatory state in which 
abnormal metabolic and physiological factors produce an increased risk of developing 
diabetes, obesity, dyslipidaemia and other cardiovascular risk factors1-3. Recent data 
reports a consistent activation of the innate immunity through the toll-like receptors 
(TLR) and its downstream signalling, suggesting not only a potential causative way, but 
also a possible perpetuator of its chronic immune stress to the organism4,5. On the other 
hand, new insights have revealed a pivotal role of the intestinal microbiota and its 
interaction with the host genetics, in the development of obesity and insulin resistance 6-
8. It has been also described the role of intestinal microbiota, its migration and its 
metabolic products systemic effects, in the activation of these TLR receptors in several 
organs, especially the Liver9,10. 
However, in spite of this new data, the relationship, causality and the 
mechanisms by which the intestinal microbiota can influence the expression of several 
immune receptors including TLR still eludes. Also, it is poorly understood the 
relationship between differential expression of TLR and the lesion of several organs 
presented in Metabolic Syndrome. 
This systematic review aims to access the most recent data about the relevance 
of intestinal microbiota and TLR expression in the development of Hepatic lesion and 
Metabolic Syndrome. 
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Methods 
A comprehensive search was performed in Pubmed and the following queries 
were used:  [("metabolic syndrome"[All Fields] AND ("microbiome"[All Fields] OR 
"microbiota"[All Fields])) OR ("metabolic syndrome"[All Fields] AND ("toll-like 
receptors"[All Fields] OR "TLRs"[All Fields]) AND ("microbiome"[All Fields] OR 
"microbiota"[All Fields]))],  and [(gut microbiota[Title] OR microbiota[Title]) AND 
(((TLR[Title]) OR Toll like receptor[Title]) OR Innate immunity[Title] )] 
From the search and after duplicates were removed, 230 studies were retrieved 
(Figure 1). Using inclusion and exclusion criteria, 35 articles were selected, analysed 
and included in this revision (Table 1).  
The principal summary measures in an outcome level were different risk ratios 
of developing obesity, diabetes, dyslipidaemia or Metabolic Syndrome in every 
experimental conditions used, difference in means of RNA or biochemical expression 
levels of markers studied and differences on histological or phonotypical assessment of 
major organs studied in a variety of experimental conditions. Subgroup analyses within 
the selected studies were also considered and taken in account.    
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TLR expression and Metabolic Syndrome: the importance of the 
innate immunity 
 
It is well known that the TLRs comprehend an extended family of pathogen-
associated molecular patterns recognition (PAMP) receptors of the innate immunity. 
These receptors allow the prompt activation of downstream signalling of MyD88-
dependent and MyD88-independent pathways in response to several antigens, mainly of 
Gram-positive and Gram-negative bacteria, and they are all linked to production of 
cytokines and enhancement of the inflammation.  
Since it is established that subclinical inflammatory processes are major 
contributors to Metabolic Syndrome, obesity and diabetes, several lines of investigation 
were made to confirm the role of innate immunity receptors and prompt activation in 
these metabolic disturbances pathogenesis 11. 
An initial study shows that there was a significant increase in both TLR2 and 
TLR4 cell surface expression and mRNA levels in monocytes of Metabolic Syndrome 
patients. This phenomenon persisted even when statistically adjusted its values to waist 
circumference and body mass index. This study also reveals that this TLR increased 
activity was significantly correlated with significant higher blood pressure and plasma 
glucose levels, and with Interleukin-1b (IL-1b), Monocyte Chemoattractant Protein-1 
(MCP-1) and Necrosis Factor-kB (NF-kB) activity, concluding that the activation of the 
TLR can count as an independent factor not only to Metabolic Syndrome but also to the 
cardiovascular risk of these patients 12.  
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The impact of TLRs is also verified in other clinical situations that are strongly 
related to Metabolic Syndrome and that can explain its participation as a causative 
factor through indirect pathways. 
On one hand, Cristina Cuda et al showed that different polymorphisms of TLR4, 
with different activation rates of this receptor, were statistically associated to different 
serum insulin levels and insulin sensitivities. The individuals with TLR4 with 299Gly 
allele were found to have higher levels of insulin and lower levels of insulin sensivity in 
comparison to the considered normal Asp homozygotes. They also found that a second 
polymorphism, an intronic SNP (rs5030728) can even modulate the relationship 
between dietary Saturated Fatty Acids and HDL cholesterol, showing that an increased 
intake of Saturated Fatty Acids was inversely related to significant lower levels of HDL 
cholesterol, in these individuals13. Steinhardt et al, on the other hand, strongly 
confirmed that another polymorphism of TLR4 is associated with syndromes of lipid 
accumulation14, thereby sustaining that TLR could be involved in the regulation of 
several metabolically substrates and increase the risk of Dyslipidaemia, a known factor 
related to Metabolic Syndrome.  
Another line of evidence using mice with +3725G/C polymorphism of TLR4, 
show that these mice have a functional decrease in their receptor activity to only 30% (P 
= 0.0001), and that they presented a statistically significant association with lower body 
mass indexes (25.5363.50 vs. 28.6064.62 kg/m2; age adjusted p = 0.023), waist 
circumferences ((89.27614.46 vs. 97.51612.59 cm; age adjusted p =0.025), and with 
higher adiponectine levels (14,5 ng/mL vs 10,6 ng/mL; p=0,021) 15. These results may 
denote a positive relation between a prompt activation of the innate immunity and 
obesity, a known factor present in Metabolic Syndrome patients. These remarkable 
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results, however, were not so strongly verified in the smoking population, and the 
authors point this factor as a potential confounding variable that must be considered on 
future studies.   
A strong association has been also described between the expression and activity 
of TLRs and the development of Type 1 and type 2 Diabetes, major factors in the 
Metabolic Syndrome pathogenesis16.  
A recent study described that Tlr2−/− genotype mice after twelve weeks of high 
fat diet, not only had more glucose tolerance and insulin sensivity than the control 
group, but also presented reduced levels of leptin, MCP-1 and Tumor Necrosis Factor-α 
(TNF-α) levels. Interestingly, insulin sensivity in TLR2 knockout mice were conserved 
in the liver causing a significant statistical reduction of hepatic glucose production and 
lower risk of developing hepatosteatosis under high-fat diet 17. This data was consistent 
with L.-H. Kuo et al study that found that TLR2 knockout mice presented lower glucose 
and insulin levels than their wild counterpart, revealing an important role of this 
receptor in glucose homeostasis. This same study also stated that mice that knockout to 
TLR2 were associated with a phenotype of decreased body weight, fat mass, lower 
number (1.21×107 in Tlr2−/− vs 2.62×107 in WT) and smaller adipocyte cells (mean 
area821 μm2 in Tlr2−/− vs 1503 μm2 in WT) 18. 
 
A meta-analysis using studies that linked Type 2 Diabetes, Metabolic Syndrome 
and D299G polymorphism of TLR4 also showed that this miss-sense variant was 
responsible for a lower response of this receptor to its ligand, Lipopolysaccharide, 
probably through a deficient recruitment of its down-signalling adapters MyD88 and 
TIR-domain-containing adapter-inducing interferon-β (TRIF) 19. The study concluded 
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that the D299G-variant was, in the Caucasian subgroup, associated to a reduced risk of 
Diabetes type 2 and metabolic syndrome. However the results were not reproducible in 
other subgroups and the authors stated that it could be explained by the differences in 
the allele frequency among different populations 16. 
On the other hand, Li Wen’s et al study detected that in spite of the strong 
relevance of environmental stimuli, in specific-pathogen free NOD mice that lacked 
MyD88 protein, the rate of type 1 Diabetes was lower when compared to its wild 
counterpart suggesting that signalling through this receptor should be a strong 
participant in the immune response that causes type 1 Diabetes 20. However, these data 
was not verified when individual KO-specific-TLR2 and 4 mice were used showing that 
these specific receptors were probably not necessary and that other innate immunity or 
TLR receptors using MyD88 intracellular signals might be responsible by the observed 
statistically significant lower responses to a diabetes-associated peptides recognized by 
specific CD8+ T cells, in type I Diabetes20. Interestingly though, this reduced risk 
observed in Myd88-negative mice was dependent on the presence of “beneficial” 
commensal microbes, since the use of antibiotics that produced germ-free MyD88-
negative mice were linked to an increase in the risk of Diabetes. In reverse, the use of 
controlled intestinal colonization with specific “beneficial” bacterial populations, after 
the antibiotic treatment, could again attenuate this risk 20. 
 
 
Microbiota and Metabolic Syndrome: a new link 
Recently, the intestinal microbiota has been progressively studied and 
knowledge of its profound influence in maintaining the human physiology and nutrition 
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has astonishingly increased 21. Using recent methods of pyrosequencing, the human gut 
microbial population has been described as the one with the highest in what concerns to 
density and variability of organisms, comprehending more than 5000 bacterial taxa and 
composed manly by Bacteroidetes and Firmicutes among other phyla less prevalent 
such as Actinobacteria, Proteobacteria, Fusobacteria, Deferribacteres and 
Deinococcus 22. Although the preponderant presence of these microorganisms in our 
gut, their impact in the human homeostasis is still not fully known and its relationships 
with several chronic diseases, especially with the Metabolic Syndrome, has open new 
lines of pathological evidence and potential therapeutic targets. 
In fact, it has become apparent that the microbiota can change metabolically the 
way we acquire nutrients or our ability to harvest energy through several mechanisms 23 
. The preponderance of these bacteria in the catalytic processing of carbohydrates in the 
human digestion or even the precise location where these metabolic reactions occur can 
influence their availability to the human organism 23. The bacteria are also associated to 
functions such as stabilizing tight junctions and promoting the secretion of 
antiinflamatory cytokines 23. In the lipid metabolism, several types of conjugated and 
free fatty acids are generated by the intestinal microbiota and play important roles in 
stimulating paracrine and endocrine peptides such as Glucagon-like Peptide (GLP) and 
peptide YY, modulating the intestine function24 . These facts point to influences to 
different energetic inputs and nutrients availability and therefore to an important 
contribution to metabolic disturbances similar to those described in obesity and 
diabetes. 
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Furthermore, it has become apparent that in spite of its location in the human 
intestine, the microbiota plays important systemic changes that are directly linked to the 
low-grade chronic inflammatory state, hugely present in the Metabolic Syndrome.  
On one hand, the characterization of the intestinal bacteria in obese model mice ( 
ob/ob) was consistent with 50% reduction of Bacteroidetes abundance and a reverse 
increase of Firmicutes when compared to lean mice 25. This unbalanced microbiota was 
found to be modulated by the composition of the diet, manly rich in fatty acids, 
independently of previous obesity or obese stat, since resistant models to high-fat 
induced obesity mice did experiment the same microbiome changes that did its wild 
counterpart 25. Moreover, it was found that a high-fat diet simulated the infusion of 
bacterial LPS defining a phenotype with development of obesity, diabetes and 
inflammatory cells infiltration in the adipose tissue. It was also found that the gut 
bacteria were able to induce the suppression of Fasting-induced adipocyte factor, 
thereby limiting the inhibition of Lipoprotein lipase in the adipocytes and promoting the 
body fat accumulation 26.  
Analogous results were obtained by M. Remely et al study, since higher 
prevalence of Firmicutes and lactic bacteria were encountered in type 2 diabetic mice in 
opposition to Bacteroidetes and F. prausnitzii. The authors also tested the influence of 
these population changes in the methylation of exons of TLR2 and 4 in the intestinal 
epithelium and described significant statistical lower methylations rates for TLR2 in 
diabetic mice and lower methylation rates for TL4 in obese mice, suggesting that there 
are important epigenetic modulations by the intestinal bacteria and that those 
modulations could probably incur in exacerbated risks of Diabetes and obesity 27.  
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These results support the previous data from C. Zhang et al study that showed 
reduced levels of gut-protecting Bifidobacteria, a phylum associated to resistance to the 
effects of LPS from the gut microbiota, in mice with a high-calorie diet. The authors 
suggest that through the modification of intestinal microbiota to a “pathogenic-like” 
microbiome, a high-calorie diet can be responsible for a loss of integrity in the barrier 
function of the intestine, the systemic spread of bacterial endotoxins and pro-
inflammatory state.  In fact the study points that a high inflammatory state was present 
in all animals with impaired glucose tolerance and increased body fat, on high-fat diet. 
The authors also revealed a predominance of Desulfovibrionaceae, sulphate-reducing 
bacteria, in high-calorie diet mice, a fact that could be related to the development of 
Metabolic Syndrome in these mice, since the disruptive properties of the sulphate in the 
intestinal barrier were present. Finally, the authors described that this transformation to 
a “pathogen-like population” through diet, seem to play a relevant role in developing 
Metabolic Syndrome that is, apparently, also independent of the host genetics and 
genomic expression 28 . 
 
Backhed F et al aimed to test the importance of microbiota during Infancy in the 
development of obesity later in life. This study showed that breastfeeding seems 
responsible for the colonization of the intestine mainly by Bifidobacteria and for a 
decrease in the Enterobacteriaceae family members. The variations to this intestinal 
microbiome ecosystem, with reduced levels of protective strains such as the 
Bifidobacteria, that are observed in 2 year old infants, had a profound impact on a 
regulator of the lipoprotein lipase called Angpt14/Fiaf, which seems to act as an 
inhibitor of the enzyme activity and responsible for an increase in the body fat 
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accumulation. This was observed in studies using mice models, which showed an 
increase in body fat tissue in germ-free Angpt14/Fiaf-deficient mice, and in non-germ 
free mice, with a functional Angpt14/Fiaf.  Also, antibiotic use in infants can cause the 
elimination of Bacteroids and a reduction in Bifidobacterium population levels, thereby 
reducing two important antiobesogenic families in the intestinal microbiota 23.  
 
TLR, Mycrobiota and Metabolic Syndrome: a global vision 
 
The activation of innate immunity through the TLR cannot be dissociated from 
the intestinal microbiota and its mutual crosstalk playing a decisive factor in the 
development of Metabolic Syndrome.  
In fact, the modulation and interaction between microbiota and TLR activation 
was investigated in a TLR2 Knockout mice study that revealed that, in spite of the 
genetic predetermination to insulin sensivity by these mice reported in studies before 
17,18, this phenotype could be drastically reversed by gut microbiota. The study 
confirmed that these TLR2 knockout mice, in non-germ free facilities, had higher levels 
of Firmicutes and Bacteroidetes in comparison to wild-type mice, and increased 
lipopolysaccharides absorption, glucose intolerance, insulin resistance and obesity. The 
authors stated that these results can be explained by an increase activation of TLR4 
receptors in the absence of TLR2 activation. They also verified increased endoplasmatic 
reticulum stress and JNK activation by the TLR4, which effects could be inhibited by a 
TLR4 antisense oligonucleotide causing an increase in glucose tolerance and sensivity 
when compared to the controls. Furthermore, in TLR2 Knockout mice, the use of a 
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mixture of antibiotics resulted in an improvement of insulin sensivity and metabolic 
status 6. 
Another recent study by C. Ubeda et al further revealed that using knock-out 
mice to a specific TLR, the impact of the absence of that certain TLR was initially 
minimal in the bacteria communities in the intestine, after a treatment with antibiotics, 
when compared to their respective wild-type mice, gathering evidence that some caution 
is advised when valorising microbial communities’ differences in these groups. 
Interestingly, the authors also stated that differences in mice’s colonies with different 
TLR deficiencies was only verified after long term breeding in isolation from each 
other, and probably with great influence from maternal transmission 29. However, 
contrary to the previous study of Vijay-Kumar M et al that described a major link 
between TLR-5 KO mice and the development of Metabolic Syndrome 30, this study 
didn’t find any difference in the intestinal microbiota colonies or in the risk of 
Metabolic Syndrome. The authors attribute these results to differential exposures in 
husbandry conditions and mice types 29. 
To add to this complex network of relations between host genetic expression and 
the environment, R. Kellermayer et al study showed an increased risk of epigenetic 
modification, DNA methylation and differential rates of transcripts in TLR2-knockout 
mice in the intestinal mucosa epithelium. The authors pointed out that these epigenetics 
and metagenomic effects, along with the modulation of the bacterial populations could 
explain the loss of the protective barrier function of the intestine and changes in the 
microbiome environment observed in the Metabolic Syndrome 31. 
13 
 
As the importance of the intestinal microbiome in the Metabolic Syndrome 
becomes more apparent, new lines of investigation have appeared, aiming the bacterial 
populations as a therapeutic hypothesis in the Metabolic Syndrome.  
A study by J. Wang et al used high fat diet mice in which was induced 
Metabolic Syndrome and subjected them to administration of one of three probiotics 
(Lactobacillus paracasei, L. rhamnosus and Bifidobacterium animalis) in order to 
modulate the gut microbiota. The results showed that these strains were able to reduce 
the weight gain, increase insulin sensivity and limit hepatic steatosis, and also that they 
were able to modulate innate immunity and the pro inflammatory state, through the 
reduced infiltration of macrophages in de adipose tissue. Moreover, the probiotic 
treatment was capable of reducing key phylotypes keen to cause Metabolic Syndrome 
(as are Desulfovibrionaceae and clostridium examples), and capable of reduce 
inflammatory processes associated to sulfate sodium-induced lesion by these bacteria. 
On the other hand, certain strains and also certain combinations of probiotic strains can 
probably provide different benefits in reversing the metabolic syndrome by a different 
impact on certain mechanisms, such as the increase of acetate, a known molecule shown 
to be able to improve obesity and diabetes on these mice 32.  
Another study, performed in humans, reported that infusion of intestinal 
microbiota from lean donors to Metabolic Syndrome subjects was able to increase 
insulin sensivity (median rate of glucose disappearance changed from 26.2 to 45.3 
mol/kg/min; P < .05), after 6 weeks. These changes were associated to an increase of 
butyrate-producing bacteria in the gut’s recipients, which is known to influence directly 
the glucose metabolism 33. Another study using probiotics rich in Lactobacillus, verified 
that those who received the probiotics had lower body mass index, waist and hip 
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measurements, and presented a reduction of fat in the abdomen and subcutaneous areas 
(p<0.01) 26. 
A randomized pilot study by B leber et al tried to unravel the effect of a  
Lactobacillus probiotic strain in the gut permeability and bacterial endotoxin presence, 
in human Metabolic Syndrome patients, covering two phenomena attributed to the 
pathogenesis of the syndrome. However, in spite of the significant increase of the gut 
permeability in the Metabolic Syndrome group of patients, the investigators didn’t find 
any difference of the endotoxin, C-reactive protein, neutrophil function and TLR 
expression levels between the group who had received the probiotic and the control 
group 34. 
 
Liver as a pivotal organ in Metabolic Syndrome 
 
The liver is a major organ on the human organism which has a profound impact 
in its metabolic and immune homeostasis 9. Indeed, its’ high efficient metabolic 
regulation of glucose, fatty acids and immune regulators and its privileged location as 
an organ that first receives blood from the gastrointestinal tract, and protects the remain 
circulation from its potential threats, make the liver a crucial participant in several 
regulatory processes. Also, it has been progressively verified that these same functions 
can be unbalanced in the Metabolic Syndrome. Usually, a prompt activation of several 
immune receptors on the hepatic immune system occurs, in response to a breakthrough 
of the epithelial barrier in the intestine, and the rise of certain bacterial populations and 
translocation 9 and this inflammatory state, therefore, can explain the development of 
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non-alcoholic fatty liver disease, promoting an increased risk to Metabolic Syndrome 
and several comorbidities such as Diabetes, Dyslipidemia and obesity 1. 
K. Sawada et al aimed to measure the expression of TLRs, TNF-α, Interleukin-
1B and phospho-interleukin-1 receptor-associated kinase 1, in the liver and small 
intestine, in non-alcoholic fatty liver disease induced mice. The authors reported a 
significant statistical increase in the inflammatory cytokines and TLR2, 4, 5 and 9 
expressions in the liver of 16 weeks mice, but no differences in the liver of 4 and 8 
weeks mice. The study also revealed that, in the intestine, it could be observed exactly 
the opposite, since all parameters were significantly decreased indicating that these 
pathways are probably inhibited in mice with NAFLD. Moreover, the treatment of these 
mice with antibiotics could attenuate the higher expression of those inflammatory 
markers and TLRs in the liver but it had little impact on the expression of these 
molecules in the small intestine of NAFLD mice 35. 
The authors further stated that, the increase on the liver TLRs expression 
appears to be selective since TLR2, 4, 5 and 9 were upregulated in primary kupffer cells 
while only TLR4 and 9 were increasingly expressed in the primary hepatocytes 35.  
 
Another recent study tested the effect TLR4 in NASH in high fat, high 
cholesterol diet mice. The results stated that, compared with wild-type, the TLR4 
mutated mice were resistant to the development of macrovesicular and microvesicular 
steatosis, hepatocellular ballooning and a fivefold increase in NASH scores. This 
phenotype was even associated with decreased TLR4 function manly in kupffer cells, 
and consequential lower levels of macrophages and cytokines. Interestingly, the study 
also included the measurement of a transcription factor named XBP-1, known to be 
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stimulated by reactive oxygen species. This protein was abrogated in the TLR4 mutant 
mice, with a simultaneously decrease of NF-kB activation and cytokine production 36.  
 
Also, TLR4 has been described as a signalling way to NAFLD development, in 
high fat diet mice, and linked to hepatic steatosis, hepatic insulin resistance and hepatic 
weight gain in these experimental circumstances. The same results were found through 
other members of TLR family such as TLR9 and TLR5 pathways 37. Finally TLR2 was 
also studied and is now apparent that its ligands are increased in obese mice and that its 
blockage can restrain its insulin resistance induction. In fact, TLR2 Knouckout mice 
exhibit lower expression of TNF-α and IL-1β inflammatory cytokines 18. 
The same rational was presented in other studies, where fructose-induced 
hepatic steatosis in mice was associated with significant induction of TLR1-4 and 
TLR6-8 along with an increase of MyD88, TNF- and iNOS levels. The authors point 
that bacterial components translocation and the prompt activation of TLRs and TLR-
depend pathways support a chronic inflammatory state that could, in the liver, end with 
the development of non-alcoholic liver disease 30,34,38.  
 
Further studying the preponderance of the reactive oxygen species in the 
NAFLD pathology, J. Henao-Mejia et al tested two inflammasome molecules and its 
effector protein in bacterial modulation and Metabolic Syndrome outcome. The study 
revealed that the progress from NAFLD to NASH was positively influenced by these 
molecules since knockout mice to inflammasome proteins (Nlrp3 and Nlrp6) were 
associated to lower effector protein (IL-18) levels, different gut microbiota and 
increased TLR4 and TLR9 agonists. These mice also had more hepatic steatosis, obesity 
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and glucose intolerance and higher rate of Porphyromonadaceae in the intestinal gut, a 
known bacterial family that increases the risk of Metabolic Syndrome in both mice and 
humans 39. 
Considering its importance, a modulation by probiotics can emerge as a 
therapeutic target to this “metabolic infection”. A recent study by S. Liang et al using 
probiotics, showed an improvement in the obesity, glucose tolerance and insulin levels 
in high fat diet fed mice. It also revealed that hepatic steatosis was reduced with 
significantly lower hepatic triglyceride content and improved histology, with the use of 
this probiotics 40. 
Another study by Y.R. Xie et al used normal and liver cirrhosis mice that were 
subjected to liver transplantation. The authors found that not only the liver cirrhosis 
groups had higher endotoxin levels and higher numbers of total bacteria, but also, that 
the referred group had an increased number of bacteria in liver and lymph nodes. The 
liver cirrhosis groups had higher rates of Enterobacteriaceae and lower Lactobacilli and 
Bacteroides and, simultaneously, had higher MUC2, MUC3 and TLR2 and 4 mRNA 
expression levels in the intestine and TLR2 and 4 increased mRNA expression levels in 
the liver. Astonishingly, these parameters had not improved until 1 month after the liver 
transplantation and, surprisingly, had not improved with the use of a lactobacillus-
enriched probiotic, suggesting probably the need of longer times of therapy or search for 
different probiotic compositions specific for each metabolic level of disturbance, either 
hepatic or systemic 41. This rational may account for important medical decisions in the 
future and possibly allow different therapeutical options become medically used in 
clinical practice. 
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Discussion 
 
For all the data stated, it is well apparent that the interaction between intestinal 
microbiota and the innate immunity might have a pivotal role in the Metabolic 
Syndrome, which impact could go way beyond the limits of the intestine and have a 
direct and systemic impact through several organs.  
Based on the results analysed, we propose that the composition of the intestinal 
microbiome, changing from a “symbiotic” population manly composed by 
Bifidobacteria and Bacteroidetes, to a more “unbalanced” one, where Firmicutes, 
Porphyromonadaceae and Desulfovibrionaceae emerge, can be modulated and 
provoked by diet and its relative composition in lipids and other factors. This dysbiotic 
environment can promptly activate several immune receptors present in the intestinal 
barrier though the recognition of PAMPs and bacterial antigens, culminating in an 
increase activation of TLR2, 4, 5 and 9, and others synergic inflammatory signalling 
pathways that were not described yet. The local pro-inflammatory profile can explain 
the altered phenotypic expression of these receptors in the intestine surface, the 
metabolic absorption disturbances observed, the increase of cytokines and inflammatory 
markers levels and the loss of barrier function of the intestine, which are all described in 
Metabolic Syndrome models 42,43. 
With this break on intestine mechanic defences, this dysbiotic bacteria and its products 
will have an easy access to the vascular space, raising the level of exogenous 
provocative antigens to the immune innate system and through its translocation 
influence the homeostasis of different organs, specially the liver because of its 
metabolic preponderance and privileged location44 (Figure 2).  
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These mechanisms synergistically account for the increase activation of TLR2, 4, 5 and 
9 in the kuppfer cells and the TLR 2, 4 and 9 in the hepatocytes and the consequential 
increase in the inflammatory products of its pathways such as TNF-α, IL-1β and iNOS. 
This chronic inflammatory state can justify the appearance of macrovesicular and 
microvesicular steatosis, and hepatocellular ballooning that counts for the NASH 
transformation45. The role and overexpression of several other molecules as xBP1 and 
NFKb can further explain this modification probably through a shift in the genetic 
expression and/or epigenetic modulation of the liver cells. 
On the other hand, throughout the organism, the antigenic activation of TLR2 and TLR4 
in various cells can be a major way of explaining the glucose intolerance, insulin 
resistance and the increased risk of Diabetes, co-morbidity associated to this syndrome. 
Furthermore, the MyD88 pathway activated by these receptors seems to be 
preponderant to this outcome, since the absence of its signalling participants or TRIF 
could account for a reduced risk of developing Diabetes5. 
The innate immunity activation can even influence the milieu of the adipose tissue, 
being responsible for a pro-inflammatory state  with increased activation of TLR4, the 
recruitment of different inflammatory cells and the production of inflammatory 
molecules. This can be the cause of the decreased adiponectine levels expression, the 
increased lipoprotein lipase functions and the explanation of the dyslipidaemia and 
obesity present in these patients 46 (Figure 3).  
Furthermore, the chronic inflammatory state is known to disturb the balance of 
coagulation/anticoagulation factors and the metabolic production of oxidative stress 
throughout the organism. These factors can further influence the regulation of delivering 
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nutrients and energetic substrates to the cells and its internal management, causing a 
most profound impact in the homeostatic equilibrium of the human body47. 
These new data opens interesting lines of evidence that a modulation of intestinal 
microbiota can be a powerful therapeutic way of influence or even reverse the 
progression of Metabolic Syndrome. The use of probiotics has revealed that through 
changes the intestinal dysbiosis, a lower pro-inflammatory profile can be achieved with 
expressive benefits in glucose tolerance, insulin sensivity, lower weight and lower 
hepatic steatosis. Although several lines of investigation are still needed in this behalf, 
the data collected so far is consistent with a potential therapeutic target in the clinical 
control of Metabolic Syndrome development and treatment48. 
In conclusion, this review detects several lines of evidence of the profound 
preponderance of early activation of TLR receptors and its interactions with a dysbiotic 
intestinal microbiota in causing several disturbances known to be implicated in 
Metabolic Syndrome (Table 2). Thus, in the near future, the understanding if there is a 
specific set of TLR overexpression associated to the different chronic metabolic 
diseases that coexist in the Metabolic Syndrome, the characterization of the modulation 
of hepatic immune receptors and cytokine production and the clarification of which are 
the major bacterial molecules that work as a factor to propagate or ameliorate the 
Metabolic Syndrome state, shall be preponderant points in the breakthrough of the 
investigation in Metabolic Syndrome medical area.  
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LEGENDS 
 
FIGURE1- Fluxogram describing the methods of data collection and articles selection. 
 
FIGURE2 – Consequences and inflammatory pathways activated during the development of 
Metabolic Syndrome in intestinal and liver tissues. The prompt activation in the intestinal 
epithelium by intestinal microbiota leads to an activation of Myd88 signaling pathways, with 
higher mRNA expression of TLR2, 4, 5 and 9, inflammatory cytokines, TNF-α, Interleucin 1β 
and MUC 2 and 3 receptors. This causes a loss barrier function of the intestine and bacterial 
translocation to other organs especially the liver. In the liver occurs Myd88 signaling pathways 
activation with increased mRNA expression of TLR2, 4 , 5, 6 and 9 in hepatocyte and kuppfer 
cells. It is also relevant the increase expression of inflammatory cytokines, NF-Kb, TNF-α and 
Interleucin-1β and decrease in anti-inflammatory pathways as XBP-1 culminating in 
transformation of hepatic tissue into non-alcoholic steatohepatitis and cirrhosis 
 
FIGURE 3- Consequences and inflammatory pathways activated during the development of 
Metabolic Syndrome in adipose and other tissues. Present in the Metabolic Syndrome 
development are increased mRNA expression of TLR 4 and inflammatory cytokines and 
decreased adiponectine production and lipoprotein lipase, in the adipose tissue. It is also present 
a macrophage invasion and inflammatory pathways activation within this tissue. Systemically it 
also occurs a prompt activation of Myd88 signaling pathways with mRNA expression of TLR 2 
and 4 and inflammatory cytokines that globally causes glucose intolerance and decreased 
insuline sensivity throughout the human organism 
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Title 
Authors Year Type of 
study 
Methods Limitations Main Conclusions 
Polymorphisms in Toll-like 
receptor 4 are associated 
with 
factors of the metabolic 
syndrome and modify the 
association 
between dietary saturated 
fat and fasting high-
density 
lipoprotein cholesterol 
Cristina Cuda, 
et al. 
2010 Prospectiv
e cohort 
study 
- Dietary assessment; 
- Anthropometrics and energy 
expenditure assessment 
- Genotyping using PCR; 
 
- Very homogeneous study population 
-Exclusion of Individuals from the study 
population with comorbidities 
associated to Metabolic Syndrome 
-Carriers of the Asp299Gly polymorphism had 
significantly higher insulin levels, higher 
homeostasis model assessment 
of insulin resistance and family history of Diabetes; 
-Carriers of the intronic polymorphism (rs5030728) 
modified the relationship between dietary SFA and 
HDL cholesterol; 
A functional 
nonsynonymous toll-like 
receptor 4 gene  
polymorphism is 
associated with metabolic 
syndrome, surrogates of 
insulin resistance, 
and syndromes of lipid 
accumulation 
Alberto Penas 
Steinhardt et 
al. 
2010 Cross 
sectional 
study 
- Clinical measurements 
- Genotyping using PCR 
-All individuals included in the study 
were men; 
- Individuals with comorbidities 
associated to Metabolic Syndrome 
were not included 
- Carriers of Asp299Asp Tlr4 polymorphism had 
higher prevalence of enlarged waist elevated 
triglyceride syndrome, hypertriglyceridemic waist 
(HW), and overweight-lipid syndrome; 
- Carriers of Asp299Asp Tlr4 polymorphism had 
higher insulin levels, and were associated to 
Metabolic Syndrome in the group of individuals 
with C-Reactive Protein levels below the 95th 
percentile; 
Functional 
Characterization of TLR4 
+3725 G/C 
Polymorphism and 
Association with 
Protection against 
Overweight 
Alberto Penas 
Steinhardt et 
al. 
2012 Prospectiv
e cohort 
study 
- Genotyping using PCR 
- Cell Culture and Transfections 
- Biochemical Analyses, 
Anthropometric and Clinical 
Measurements 
- No exclusion criteria were used - Carriers of 11350G/C TLR4 polymorphism was 
associated with a reduction of 30% of TLR4 gene 
activity; 
- Carriers of 11350G/C TLR4 polymorphism had 
also less weight, lower BMI, waist circumference 
and higher adiponectin levels; 
The Asp299Gly 
Polymorphism Alters TLR4 
Signaling by 
Interfering with 
Recruitment of MyD88 and 
TRIF 
Leandra 
Figueiroa et 
al. 
2012 Experime
ntal study 
- Cell culture and Transfections 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- Antagonists of the TLR4-MyD88 were 
not studied 
- Mice that carried D299G polymorphism of the 
TLR4 revealed comparable total TLR4 expression, 
TLR4–MD2 interactions, and LPS binding, in 
comparison to wild type mice. However, they were 
associated with macrophages that failed to elicit 
LPS-mediated induction of TNF-a and IFN-b mRNA 
levels and diminished LPS-driven interaction of 
MyD88 and TRIF with TLR4; 
Toll-like receptor 4 D299G F.S. Belforte, 2012 Meta- ----- -Possible publication bias - It was reported a significant association between 
TABLE 1 – Main Characteristics of animal and clinical studies included in the systematic revision 
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polymorphism in 
metabolic disorders: 
a meta-analysis 
et al. analysis  - Low number of studies included TLR4 D299G polymorphism and metabolic 
disorders (T2DM and 
Met-S) risk (OR = 0.566, 95 % CI: 0.347–0.925, p 
=0.023) particularly in Caucasians; 
Innate immunity and 
intestinal microbiota in 
the development of 
Type 1 diabetes 
Li Wen, et al. 2008 Experime
ntal study 
- Histopathology evaluation 
- Sequencing and phylogenetic 
analysis 
- Other parallel signalling pathways 
such as TRIF were not considered 
- Specific-pathogen free (SPF) Non-Obese Diabetic 
mice lacking MyD88 protein did not develop Type 
1 Diabetes 
- MyD88-deficiency changes the 
composition of the distal gut microbiota 
-  The exposure to the microbiota of Specific 
Pathogen Free NOD.MyD88-negative donors 
attenuates Type 1Diabetes found  in Germ Free 
NOD recipients; 
Toll-like receptor 2-
deficient mice are 
protected from insulin 
resistance and beta cell 
dysfunction induced by a 
high-fat diet 
J.A. Ehses, et 
al. 
2009 Experime
ntal study 
- Indirect calorimetry and 
physical activity assessment 
- Immunohistochemistry 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- Inability to conclude whether the 
observed reductions in tissue 
inflammation 
in vivo are due to an immune cell, or 
parenchymal 
cell, origin. 
- Mice with Tlr2−/− genotype were protected from 
the adverse effects of high fat diet 
compared with Tlr2+/+ littermate controls; 
- Female Tlr2−/− mice showed pronounced 
improvements in glucose tolerance, 
insulin sensitivity, and insulin secretion following 
20 weeks of HFD feeding; 
Toll-like receptor 2 
deficiency improves insulin 
sensitivity 
and hepatic  insulin 
signalling in the mouse 
L.-H. Kuo, et 
al. 
2010 Experime
ntal study 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
- Protein analysis 
 
- Further studies are needed to account 
for the mechanistic insight of the 
improvement of insulin sensivity with 
TLR2 deficiency 
- Aged or high-fat-fed TLR2-deficient mice were 
protected from obesity and adipocyte hypertrophy 
compared with wild-type mice; 
- Mice lacking TLR2 exhibited improved glucose 
tolerance and insulin sensitivity regardless of 
feeding them regular chow or a high-fat diet; 
- The attenuated hepatic inflammatory cytokine 
expression and related signalling are correlated 
with increased insulin action specifically in the liver 
in TLR2-deficient mice; 
Familial transmission 
rather than defective 
innate immunity shapes 
the distinct intestinal 
microbiota of TLR-deficient 
mice 
Carles Ubeda, 
et al. 
2012 Experime
ntal study 
- High-throughput sequencing 
of 16S rRNA genes 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- Environmental intestinal colonization 
besides maternal origin was not 
studied 
- The composition of intestinal microbiota was not 
significantly different between MyD88-, TLR2-, 
TLR4-, TLR5-, and TLR9-deficient mice and their 
respective wild-type (WT) littermates; 
- Differences between different knockout mice 
groups were due to long term divergence in 
isolation from each other; 
- The long term differences in intestinal microbiota 
3 
 
composition resulted mainly from maternal 
transmission; 
Metabolic syndrome and 
altered gut microbiota in 
mice lacking Toll-like 
receptor 5. 
Vijay-Kumar 
M., et al. 
2010 Experime
ntal study 
- Bacterial trsnlocation to 
experimental purposes 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
Other potential correlations with other 
TLR were not considered limiting the 
rational for TLR5 role and 
preponderance 
Toll-like receptor 5 knockout mice exhibited 
hyperphagia, hyperlipidemia, hypertension, insulin 
resistance, and increased adiposity; 
- Transfer of the gut microbiota from TLR5-
deficient mice to wild-type germ-free mice 
conferred many features of metabolic syndrome to 
the recipients; 
Colonic mucosal DNA 
methylation, immune 
response, 
and microbiome patterns 
in Toll-like receptor 
2-knockout mice 
Richard 
Kellermayer, 
et al. 
2011 Experime
ntal study 
- Histological assessment 
- Pyrosequencing 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
 
- Intestinal microbiome changes were 
not as reproductive on human tissue 
colonic samples 
- In the TLR2 knockout mice, the expression of 
genes involved in immune processes were found 
significantly different as well as epigenomic and 
transcriptomic modifications associated with 
altered microta composition; 
- Several bacterial species, including members of 
the Firmicutes were significantly different in 
abundance 
between WT and Tlr2_/_ animals; 
A human gut microbial 
gene catalogue 
established by 
metagenomic sequencing 
Junjie Qin, et 
al. 
2010 Prospectiv
e cohort 
study 
- Stool sampling; 
- real-time 
quantitative PCR 
- Library database construction 
 
- Only usage of faecal samples. - Over 99% of the genes are bacterial, indicating 
that the entire cohort harbours between 1,000 and 
1,150 prevalent bacterial species and each 
individual at least 160 such species, which are also 
largely shared; 
- This Large intestinal microbiome is responsible of 
several functions known to be important to the 
host–bacterial interaction, 
such as degradation of complex polysaccharides, 
synthesis of short-chain fatty acids, indispensable 
amino acids and vitamins; 
Microbiota and epigenetic 
regulation of 
inflammatory mediators in 
type 2 diabetes 
and obesity 
M. Remely, et 
al. 
2014 Experime
ntal study 
- Pyrosequencing 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- The groups were not entirely 
comparable by possible confounders in 
the selection of mice characteristics 
- higher ratio of Firmicutes/ 
Bacteroidetes in type 2 diabetics was observed 
when compared to lean controls and obese, as 
well as lactic acid bacteria; 
- Methylation analysis of four CpGs in the first exon 
of TLR4 showed significantly lower methylation in 
obese individuals and methylation of seven CpGs 
in the promoter region of TLR2 was significantly 
lower in type 2 diabetics mice; 
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- The methylation levels of both TLRs were 
significantly correlated with body mass index 
Interactions between gut 
microbiota, host 
genetics and diet relevant 
to development 
of metabolic syndromes in 
mice 
CHenhong 
Zhang, et al. 
2010 Experime
ntal study 
- Pyrosequencing 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
The Bifidobacteria effects were not 
analysed since this group of bacteria 
was actually removed from guts fed 
with High Fat Diet possibly due to the 
much longer feeding time. 
- Diet changes explained 57% of the total structural 
variation in gut microbiota, 
whereas genetic mutation accounted for no more 
than 12% 
- Desulfovibrionaceae, were dominant in all 
animals with impaired glucose tolerance, most 
significantly in the wild-type with high fat diet 
group, which had the highest calorie intake and 
the most serious MS phenotypes 
Modulation of gut 
microbiota during 
probiotic-mediated 
attenuation of metabolic 
syndrome in high fat diet-
fed mice 
Jingjing Wang, 
et al. 
2014 Experime
ntal study 
- Enzyme-linked 
immunosorbent assay 
- Histomorphology and 
immunohistochemistry 
- pyrosequencing 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- Only usage of faecal samples. -The use of the probiotics was responsible for a 
reduction of the bacteria positively related to 
metabolic Syndrome 
- A probiotic composed by Bifidobacterium 
animalis subsp. lactis I-2494 was even responsible 
by a decreased adipose and hepatic TNF-alfa gene 
expression. 
Transfer of Intestinal 
Microbiota From Lean 
Donors Increases Insulin 
Sensitivity in Individuals 
With Metabolic Syndrome 
ANNE VRIEZE, 
et al. 
2012 Prospectiv
e cohort 
study 
- Gut Microbiota Transfer 
Procedures 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
- Biochemical analysis of Fecal 
samples 
- Diet composition was not controlled 
in healthy control patients 
- After infusion of microbiota from lean donors, all 
groups presented an increase in insulin sensivity of 
recipients and an increase of butyrate-producing 
intestinal microbiota 
Increased Toll-like 
receptor Activity in 
Patients With Metabolic 
Syndrome 
ISHWARLAL 
JIALAL, et 
al. 
2012 Prospectiv
e cohort 
study 
- Magnetic cell separation 
- RT-PCR 
- Fluorescent in-situ 
hybridization. 
-The control group could have less than 
2 features of Metabolic Syndrome 
-Potential differences in other cells 
expression 
-Circulating levels of high-sensitivity C-reactive 
protein, interleukin (IL)-1b, IL-6, 
IL-8, and soluble tumor necrosis factor receptor 1 
(sTNFR1) were significantly increased in MetS 
versus control subjects 
-Significant increase in both TLR2 and TLR4 surface 
expression and mRNA on monocytes after 
adjustment for waist circumference. 
- Plasma free fatty acids and 
endotoxin were increased in Metabolic Syndrome 
patients but only correlated significantly 
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considering TLR4 expression. 
The influence of probiotic 
supplementation on gut 
permeability 
in patients with metabolic 
syndrome: an open label, 
randomized 
pilot study 
B. Leber, et al. 2012 Randomiz
ed pilot 
study 
- Fluorescent in-situ 
hybridization.- 
- cytometric analysis 
- Determination of endotoxin excluding 
important pathogens present in human 
gut 
- Gut permeability was significantly increased in 
Metabolic Syndrome compared with controls 
- LBP and sCD14 levels were not significantly 
different from healthy controls. 
- High-sensitive C-reactive protein and LBP levels 
slightly but significantly increased after 3 months 
within the probiotics group. 
- Neutrophil function and TLR expression did not 
differ from healthy controls or within the patient 
groups. 
Augmented hepatic Toll-
like receptors by fatty 
acids trigger 
the pro-inflammatory 
state of non-alcoholic fatty 
liver 
disease in mice 
Koji Sawada, 
et al. 
2014 Experime
ntal study 
- Cell culture 
- Biochemical analyses 
- Histopathological evaluation 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
- Immunohistochemistry/ 
immunocytochemistry 
 
- The intestinal microbioma was not 
characterized nor its potential role in 
the results obtained 
- The expression of inflammatory cytokines such as 
TNF, IL-1β, and TLR-2, -4, -5, and -9 was increased 
in the liver, but decreased in the small intestine of 
High Fat Diet-fed mice in vivo. 
- The expression of TLRs in primary hepatocytes 
and Kupffer cells was increased by treatment with 
palmitic acid 
Toll-like receptor-4 
mediates obesity-induced 
non-alcoholic 
steatohepatitis through 
activation of 
X-box binding protein-1 in 
mice 
Dewei Ye, et 
al. 
2014 Experime
ntal study 
- Cell culture 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- Use of a new understudied mice 
model for representation of human 
NASH 
- The model used with a high fat and high calorie 
diet developed typical pathological features of 
NASH, which is associated with obesity and the 
metabolic syndrome 
- mice lacking functional TLR4 were resistant to 
HFHC diet-induced liver inflammation and injury 
and were less 
susceptible to the diet-induced production of 
reactive oxygen species (ROS) and 
proinflammatory cytokines 
- a transcription factor  XBP-1 involved in the 
unfolded protein responses, was activated in the 
liver by an HFHC diet, whereas XBP-1 activation 
was abrogated in TLR4 knockout mice. 
Toll-like receptors 1–9 are 
elevated in livers with 
fructose-induced 
hepatic steatosis 
Sabine 
Wagnerberge
r, et al. 
2012 Experime
ntal study 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
- Immunostaining and histology 
- Mechanisms of hepatic TLR activation 
were not studied 
- The accumulation of Triacylglycerol found in the 
livers of fructose-fed mice was associated with a 
significant induction of TLR 1–4 and 6–8. 
- Plasma RBP4 concentration and hepatic mRNA 
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evaluation 
- Western Blotting 
expression levels of TNF-a, iNOS, MyD88 and 
number of F4/80 positive cells of fructose-fed 
animals were significantly higher than those of 
controls; 
- These effects of fructose were attenuated in 
antibiotic-treated mice 
Inflammasome-mediated 
dysbiosis regulates 
progression of 
NAFLD and obesity 
Jorge Henao-
Mejia, et al. 
2012 Experime
ntal study 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
- Immunostaining and histology 
evaluation 
-Transmission electron 
microscopy 
-Bacterial 16S rRNA amplicon 
sequencing 
 
- False negative and False positive 
results could be allocated to the 
measure of PAMPs method used 
- Inflammasome deficiency-associated changes in 
the configuration of the 
gut microbiota are associated with exacerbated 
hepatic steatosis and inflammation through influx 
of TLR4 and TLR9 agonists and enhanced hepatic 
TNF-α 
- co-housing of inflammasome-deficient 
animals to wild type mice results in exacerbation 
of hepatic steatosis, glucose intolerance, 
andobesity 
- NLRP3 and NLRP6 inflammasomes govern the 
rate of progression of multiple 
metabolic syndrome-associated abnormalities, 
 
Probiotics Antigens 
Stimulate Hepatic NKT 
cells 
Shuwen Liang, 
et al. 
2013 Experime
ntal study 
- Histology 
- Flow citometry 
- Immunofluorescence 
expression assessment 
- NKT cells participation in the 
development of NASH was not clear 
- High dose of selected probiotic was effective for 
the improvement of hepatic NKT cell depletion, 
obesity and steatosis. 
-Disruption of TLR4 signaling does not protect HF 
diet induced NKT cell depletion and 
metabolic dysfunction 
 
Intestinal Microbiota and 
Innate Immunity-Related 
Gene Alteration in 
Cirrhotic Rats with Liver 
Transplantation 
Y.R. Xie, et al. 2011 Experime
ntal study 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
- Bacterial translocation for 
experimental groups protocol 
 
- The experimental model acquisition 
method could influence intestinal 
bacteria directly and influence its 
modifications 
- Liver cirrhosis and liver cirrhosis with transplant 
were associated with higher endotoxin levels and 
with higher incidence of bacterial translocation to 
liver and mesenteric lymph nodes, and with the 
number of total bacteria. 
-Mucins (MUC2, MUC3) and Toll-like receptors 
(TLR2, TLR4) messenger RNA (mRNA) expression 
were significantly higher in the cirrhosis groups 
than the control group 
Diversity of the Human 
Intestinal Microbial Flora 
Paul B. 
Eckburg, et al. 
2005 Case 
control 
- RNA isolation, reverse 
transcription, and real-time 
- Pyrosequencing as the most accurate 
method of bacterial identification was 
- A majority of the bacterial sequences 
corresponded to uncultivated species and 
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study quantitative PCR 
 
 
not used novel microorganisms 
- significant intersubject variability and differences 
between stool and mucosa community 
composition were observed 
The gut microbiota as an 
environmental factor that 
regulates fat storage 
Fredrik 
Ba¨ckhed, et 
al. 
2004 Experime
ntal study 
- Measurement of Total Body 
Fat Content and Metabolic Rate 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
 
- Microbiota composition was not 
accessed 
- adult germ-free mice with a normal microbiota 
harvested from the distal intestine (cecum) of 
conventionally raised animals produces a 60% 
increase in body fat content and insulin resistance 
despite reduced food intake. 
- microbiota promotes absorption of 
monosaccharides from the gut lumen, with 
resulting induction of de novo hepatic lipogenesis 
Mechanisms underlying 
the resistance to diet-
induced 
obesity in germ-free mice 
Fredrik 
Ba¨ckhed, et 
al. 
2007 Experime
ntal study 
- Immunoblotting 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- The bacterial microbiota was not 
assessed or characterized and could 
explain for the differences observed in 
Fiaf-deficient mice 
- The preponderance of mechanisms in 
the explanation of the increased 
obesity  was not ascertained 
statistically 
- Germ-free mice were associated with a lean 
phenotype  and increased levels of AMPK 
expression in liver and muscle samples 
- knockout mice lacking fasting-induced adipose 
factor are not protected from diet-induced obesity 
Human gut microbes 
associated with obesity 
Ruth E., et al. 2006 Prospectiv
e cohort 
study 
- Pyrosequencing; 
- Real-Time quantitative PCR. 
- Low number of participants in the 
study 
- Bacterial lineages were remarkably constant 
within people over time 
- Before diet therapy, obese people 
had fewer Bacteroidetes (P<0.001) and more 
Firmicutes (P=0.002) than did lean controls 
- with time, the relative abundance 
of Bacteroidetes increased (P<0.001) and the 
abundance of Firmicutes decreased (P=0.002), 
irrespective of diet type 
Deficiency in myeloid 
differentiation factor-2 
and toll-like receptor 4 
expression attenuates 
nonalcoholic 
steatohepatitis and 
fibrosis in mice 
Timea Csak, 
et al. 
2011 Experime
ntal study 
- histological evaluation 
- flow cytometry analysis 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- Participation of other TLR that could 
account for the results obtained were 
not considered 
- Features of NASH were significantly attenuated in 
MD-2 KO and TLR4 KO mice. 
-Serum alanine aminotransferase, was increased in 
controls but was attenuated in MD-2 KO and TLR4 
KO mice. 
- Inflammatory activation, indicated 
by serum TNF-alfa and nictoinamide adenine 
dinucleotide phosphate oxidase complex mRNA 
expression and activation, was significantly 
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TABLE 1 – Main Characteristics of animal and clinical studies included in the systematic revision (includes “Authors”, “Year of publication”, “Type of Study”, “Methods”, 
“Limitations” and “Main Conclusions”  
 
 
 
 
 
 
lower in MCD diet-fed MD-2 KO and TLR4 KO 
compared with corresponding genotype control 
mice. 
Increased oxidative stress 
in obesity 
and its impact on 
metabolic syndrome 
Shigetada 
Furukawa, et 
al. 
2004 Experime
ntal study 
- Biochemical measurements. 
- RNA isolation, reverse 
transcription, and real-time 
quantitative PCR 
 
- The reactive oxygen species role was 
not determined 
- Diabetes and other comorbidities of 
the mice model were not taken in 
account in the statistical analysis 
- Production of ROS increased selectively in 
adipose tissue of obese mice, accompanied by 
augmented expression of NADPH oxidase and 
decreased expression of antioxidative enzymes. 
- In cultured adipocytes, elevated levels of fatty 
acids 
increased oxidative stress via NADPH oxidase 
activation, and oxidative stress caused 
dysregulated production 
of adipocytokines 
- in obese mice, treatment with NADPH oxidase 
inhibitor reduced ROS production in adipose 
tissue, attenuated the dysregulation of 
adipocytokines, and improved diabetes, 
hyperlipidemia, and hepatic steatosis 
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TABLE 2 – Principal proposed mechanisms in the development of Metabolic Syndrome [here, ↑ represents an augment and ↓ a decrease]. 
 Toll-like receptor activation 
Biochemical molecules 
expression 
Intestinal Microbiota 
modifications 
Phenotypical/Hysthological 
Modifications 
Diabetes 
- ↑ TLR4 and TLR2  
expression levels 
- ↑ MyD88 and 
TRIF signalling 
pathways 
- ↑ Insulin levels 
- ↑ Leptin, MCP-1 and TNF-α 
expression levels 
- ↑ CD8+ T cells activation (↑ 
risk of Diabetes type 1) 
- ↑ Firmicutes and  ↓ 
Bacteroidetes and F. prausnitzii 
 
- Glucose Intolerance, ↓ insulin 
sensivity 
Dyslipidemia 
- ↑TLR4 
expression levels 
 
- ↑ Saturated Fatty acids and 
↓HDL cholesterol levels 
- ↓ Adiponectine levels 
-↑ Lipoprotein Lipase and ↓ 
Fasting-induced adipocyte 
factor ( Angpt14/Fiaf ) activities 
- ↑ Firmicutes and ↓ 
Bacteroidetes 
- Obesity 
- Increased macrophage 
infiltration in adipose tissue 
-Smaller Adipocytes 
NASH 
- ↑ TLR2 and 
TLR4, 5 and 9 
expression levels 
- ↑IL-1β, phospho-interleukin-
1 receptor-associated kinase 1 
and TNF-α expression levels 
- ↑ XBP-1, iNOS and NF-kB 
expression levels 
- ↑ Nlrp3, Nlrp6 and IL-18 
expression levels 
- ↑MUC2 and 3 intestinal 
activity 
- ↑ Firmicutes,  
Pophyromonadaceae and  
Enterobacteriaceae 
- ↓Bacteroidetes, Lactobacilli and 
Bacteroides 
- Macrovesicular and 
microvesicular hepatic steatosis 
and hepatocellular ballooning 
- Obesity and glucose intolerance 
Metabolic 
Syndrome 
- ↑ TLR2 and TLR4 
expression levels 
 
 
- ↑IL-1β, MCP-1 and NF-kB 
expression levels; 
- ↑ Insulin levels and ↓Insulin 
sensivity 
 
 
 
- ↑ Firmicutes,  
Desulfovibrionaceae, and 
Pophyromonadaceae 
- ↓Bacteroidetes and  
Bifidobacteria 
- Higher waist circunferences and 
body weight 
- Diabetes (with all above) 
- Dyslipidemia (with all above) 
- NASH (with all above) 
TABLE 2 – Principal proposed mechanisms in the development of Metabolic Syndrome 
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